Lisa R Sammaritano1,2. 1. Weill Cornell Medicine, New York, NY, 10021, USA. sammaritanol@hss.edu. 2. Hospital for Special Surgery, New York, NY, 10021, USA. sammaritanol@hss.edu.
Abstract
PURPOSE OF REVIEW: Use of exogenous estrogen carries significant risk for patients with prothrombotic disorders including those with antiphospholipid antibody (aPL) and antiphospholipid syndrome (APS). This review summarizes current knowledge of contraceptive and other hormone therapies for aPL-positive and APS women and highlights knowledge gaps to guide future research. RECENT FINDINGS: Studies support very low risk for most progestin-only contraceptives in patients with increased thrombotic risk, but suggest increased VTE risk with depot-medroxyprogesterone acetate. Highest efficacy contraceptives are intrauterine devices and subdermal implants, and these are recommended for women with aPL/APS. Progestin-only pills are effective and low risk. Perimenopausal symptoms may be treated with nonhormone therapies in aPL/APS patients: vasomotor symptoms can improve with nonhormonal medications and cognitive behavioral therapy, and genitourinary symptoms often improve with intravaginal estrogen that has limited systemic absorption.
PURPOSE OF REVIEW: Use of exogenous estrogen carries significant risk for patients with prothrombotic disorders including those with antiphospholipid antibody (aPL) and antiphospholipid syndrome (APS). This review summarizes current knowledge of contraceptive and other hormone therapies for aPL-positive and APSwomen and highlights knowledge gaps to guide future research. RECENT FINDINGS: Studies support very low risk for most progestin-only contraceptives in patients with increased thrombotic risk, but suggest increased VTE risk with depot-medroxyprogesterone acetate. Highest efficacy contraceptives are intrauterine devices and subdermal implants, and these are recommended for women with aPL/APS. Progestin-only pills are effective and low risk. Perimenopausal symptoms may be treated with nonhormone therapies in aPL/APSpatients: vasomotor symptoms can improve with nonhormonal medications and cognitive behavioral therapy, and genitourinary symptoms often improve with intravaginal estrogen that has limited systemic absorption.
Authors: S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis Journal: J Thromb Haemost Date: 2006-02 Impact factor: 5.824
Authors: Brooke Winner; Jeffrey F Peipert; Qiuhong Zhao; Christina Buckel; Tessa Madden; Jenifer E Allsworth; Gina M Secura Journal: N Engl J Med Date: 2012-05-24 Impact factor: 91.245
Authors: Victor Moreno; F Xavier Bosch; Nubia Muñoz; Chris J L M Meijer; Keerti V Shah; Jan M M Walboomers; Rolando Herrero; Silvia Franceschi Journal: Lancet Date: 2002-03-30 Impact factor: 79.321
Authors: Anna E DeNoble; Kelli S Hall; Xiao Xu; Melissa K Zochowski; Kenneth Piehl; Vanessa K Dalton Journal: Obstet Gynecol Date: 2014-06 Impact factor: 7.661
Authors: Steven W Champaloux; Naomi K Tepper; Kathryn M Curtis; Lauren B Zapata; Maura K Whiteman; Polly A Marchbanks; Denise J Jamieson Journal: Obstet Gynecol Date: 2015-12 Impact factor: 7.661